|
Disparities within luminal breast cancer: Clinical and molecular features of African American and non-Hispanic white patients. |
|
|
Research Funding - Abbvie (Inst); Merck Sharp & Dohme (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
Leadership - SEngine Precision Medicine |
Stock and Other Ownership Interests - 3rdEyeBio; New Equilibrium Biosciences; Novilla; Sengine precision medicine |
Consulting or Advisory Role - Novartis; Puma Biotechnology; Sanofi; Seagen |
Speakers' Bureau - bioTheranostics; Seagen |
Research Funding - Agendia; Genentech/Roche (Inst); SignalOne Bio |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
|
Stock and Other Ownership Interests - Agendia |
Patents, Royalties, Other Intellectual Property - NXT Biologics |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
Employment - Baptist MD Anderson Cancer Center |
Speakers' Bureau - Agendia; Novartis |
Research Funding - Agendia; Merck; Novartis; Pfizer; Seagen |
|
|
Employment - For-profit pharmacy (I) |
|
Consulting or Advisory Role - Dune Medical Devices |
Research Funding - Cardinal Health; Dune Medical Devices; Medtronic |
Patents, Royalties, Other Intellectual Property - Johns Hopkins University |
Expert Testimony - Agendia |
Travel, Accommodations, Expenses - Agendia; ZEISS |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |